GluBio Therapeutics is a company dedicated to the discovery and development of innovative small molecule medicines by harnessing the power of targeted protein degradation (TPD). Our team is comprised of seasoned drug developers with deep knowledge and expertise in TPD drug discovery.
Using a proprietary TPD discovery platform and robust screening capabilities, we are advancing a diverse pipeline of highly selective small-molecule degraders across multiple therapeutic areas.
Our mission is to develop powerful therapies to treat human diseases and improve the quality of life of patients. The company, headquartered in San Diego, CA, has research operations in both the United States and China.